Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

SHE:300357 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	933.68	921.46	840.75	894.88	804.12	633.42
Other Revenue	3.94	3.94	7.44	1.14	3.58	2.79
Revenue	937.62	925.39	848.19	896.02	807.69	636.21
Revenue Growth (YoY)	6.39%	9.10%	-5.34%	10.94%	26.95%	-0.49%
Cost of Revenue	46.36	44.81	40.19	42.51	34.44	28.54
Gross Profit	891.25	880.58	808	853.5	773.25	607.67
Selling, General & Admin	446.32	434.65	385.28	359.63	333.97	263.18
Research & Development	118.96	119.88	112.2	106.02	87.93	61.27
Other Operating Expenses	12.66	7.84	4.57	4.53	3.78	3.27
Operating Expenses	577.89	563.23	501.05	471.43	427.23	328.01
Operating Income	313.36	317.36	306.95	382.07	346.02	279.66
Interest Expense	-0.96	-1.06	-1.31	-0.44	-0.36	-
Interest & Investment Income	35.37	35.81	32.87	28.35	29.03	24.63
Currency Exchange Gain (Loss)	0	0	0	-0	-0	-0.01
Other Non Operating Income (Expenses)	-0.01	-0.34	-0.26	-0.15	-0.17	-0.17
EBT Excluding Unusual Items	347.75	351.76	338.25	409.82	374.52	304.11
Gain (Loss) on Sale of Investments	2.79	2.43	-0.67	-0.88	-0.1	2.66
Gain (Loss) on Sale of Assets	0.91	0.57	-	-0.27	-	-
Asset Writedown	-1.42	-1.42	-0.58	-43.23	-0.1	-0.01
Other Unusual Items	11.19	11.72	8.95	33.3	18.67	15.85
Pretax Income	361.23	365.06	345.96	398.75	393	322.62
Income Tax Expense	59.25	60.72	50.43	63.02	66.71	52.89
Earnings From Continuing Operations	301.97	304.34	295.52	335.73	326.29	269.72
Minority Interest in Earnings	12.98	13.48	14.66	13.05	11.7	8.72
Net Income	314.96	317.82	310.18	348.77	337.99	278.45
Net Income to Common	314.96	317.82	310.18	348.77	337.99	278.45
Net Income Growth	-0.62%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Shares Outstanding (Basic)	524	524	524	524	524	524
Shares Outstanding (Diluted)	524	524	524	524	524	524
Shares Change (YoY)	0.01%	-0.00%	-	-0.00%	0.00%	-0.00%
EPS (Basic)	0.60	0.61	0.59	0.67	0.65	0.53
EPS (Diluted)	0.60	0.61	0.59	0.67	0.65	0.53
EPS Growth	-0.63%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Free Cash Flow	181.55	133.12	154.61	159.62	236.33	186.06
Free Cash Flow Per Share	0.35	0.25	0.29	0.30	0.45	0.35
Dividend Per Share	0.220	0.220	0.185	0.200	0.201	0.160
Dividend Growth	18.92%	18.92%	-7.50%	-0.50%	25.62%	-11.11%
Gross Margin	95.06%	95.16%	95.26%	95.25%	95.74%	95.51%
Operating Margin	33.42%	34.29%	36.19%	42.64%	42.84%	43.96%
Profit Margin	33.59%	34.34%	36.57%	38.92%	41.85%	43.77%
Free Cash Flow Margin	19.36%	14.39%	18.23%	17.82%	29.26%	29.25%
EBITDA	359.82	360.81	338.38	402.44	366.11	294.68
EBITDA Margin	38.38%	38.99%	39.89%	44.91%	45.33%	46.32%
D&A For EBITDA	46.46	43.45	31.43	20.37	20.08	15.03
EBIT	313.36	317.36	306.95	382.07	346.02	279.66
EBIT Margin	33.42%	34.29%	36.19%	42.64%	42.84%	43.96%
Effective Tax Rate	16.40%	16.63%	14.58%	15.80%	16.97%	16.39%
Revenue as Reported	937.62	925.39	848.19	896.02	807.69	636.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.